Discover innovative solutions to the key challenges of the drug safety industry
Hoda Eid | Manager, Adverse Drug reactions division Health Canada
Hoda Eid holds a Ph.D. from the Université de Montréal in Canada and a Post-Doctoral fellowship from the Brigham and Women’s Hospital and Harvard Medical School in Boston. She returned to Canada in 1992 as an Assistant Professor at the University of Ottawa and a Research Scientist at the Ottawa Heart Institute. In her research carrier, Dr. Eid isolated a cell line to investigate cardiovascular development and cardiac cell differentiation and regeneration in vitro. This cell line has been requested and shared with over thirty laboratories in the US and in Europe. She joined Health Canada in 1998 as a Medical Evaluator of clinical trial applications and as the Associate Director to the Senior Medical Advisor from 2003-2006 when she accepted to lead the pre-market safety surveillance in Health Canada.
Share this
Appearances at this years' conference:
Day one AM - Wednesday 18th April 2012
@ 11.45
Panel Session: The existing harmonisation practices are not working, how can we do this better?
• Is it possible to achieve global harmonisation of safety
regulations and practices?
› Hoda Eid, Manager, Adverse Drug reactions division, Health Canada
Day Two - Thursday 19th April 2012
@ 14.45
Safe access to innovative therapies: when and why safety surveillance can fail
- Evolving global pre-market safety surveillance landscape
- Challenges in the current regulatory environments
- Operational barriers: Importance of standardised techniques
- Impact on drug development and drug safety
- Regulator's perspective
› Hoda Eid, Manager, Adverse Drug reactions division, Health Canada